Sometimes depression doesn’t get better, even with treatment.
Could psychedelics be helpful in your healing process?
OUR TREATMENT PROTOCOLS ARE PATIENT-CENTERED, SAFE, AND CLINICALLY PROVEN
Our psychotherapists are trained to provide a variety of evidence-based approaches to psychedelic assisted therapy in combination with substances like psilocybin, MDMA, and Ketamine.
We understand the importance of active therapist participation before, during, and after the psychedelic experience.
Our treatment protocol empowers therapists to provide the best possible patient care.
Psychedelics, including substances like psilocybin, MDMA, and Ketamine, have gained recognition in therapy for their ability to induce altered states of consciousness and promote neural plasticity.
They show promise in treating conditions like depression, anxiety, substance abuse, and PTSD.
PSILOCYBIN RESEARCH AND POTENTIAL
Roland Griffiths, Ph.D., presented a TEDMED talk in 2015 about the therapeutic and consciousness potential of psilocybin. Research to date demonstrate safety of psilocybin in regulated spaces facilitated by medical team over a series of guided sessions; and as a part of cognitive behavioral therapy, psilocybin helps in reducing anxiety in some cancer patients, and in facilitating smoking cessation for some.
HOSPITALS IN AMERICA OFFERING PSYCHEDELIC THERAPY
Government of Canada invests nearly $3 million to study the potential benefits of psilocybin-assisted psychotherapy
New research on psychedelic-assisted treatment has demonstrated positive results. JAMA published a study in August that found when patients with alcohol use disorder (AUD) had psilocybin-assisted treatment, their percentage of heavy drinking days was lowered significantly.
“We have great outcomes on clinical trials, which just validate everything that we saw in some of the academic trials over the last 10 years or so,” Levy said.
The industry is also closely watching the Multidisciplinary Association for Psychedelic Studies’ (MAPS) research on psychedelics treatment for PTSD. In 2022, MAPS completed its second Phase 3 trial on MDMA to support the substance’s FDA approval. The organization projects that MDMA-assisted therapy will receive FDA evaluation in 2023. MAPS currently has an FDA breakthrough designation for its therapy.
In MAPS’ first Phase 3 study of MDMA, researchers found that 88% of participants with severe PTSD taking MDMA significantly reduced their symptoms, compared to 60% of placebo patients.
Some industry insiders see this as the research that will lead to the first FDA clearance.
“I think you’re going to start to see MAPS potentially go first with its MDMA program for post-traumatic stress disorder,” Greg Mayes, president and CEO of Reunion Neuroscience, told BHB. “I think all expectations are that the product could be on the market and available in very late 2023, or very early 2024. But that’s going to be an important first mover.”
Reunion Neuroscience is a biopharmaceutical company focused on developing therapeutics for mental health conditions. Its lead asset is a novel psychedelic compound that treats postpartum depression and other mental health conditions.
An FDA approval could clear the way for other psychedelic-assisted treatments coming down the pipeline.
SCHEDULE A FREE CONFERENCE CALL WITH A SENIOR TEAM MEMBER
– We collect a brief history of the problem
– We explain additional testing/evaluation needed
– We explain the costs
FINANCING OPTIONS ARE AVAILABLE
See How The Montreal Neurotherapy Center Can Help!
Teletherapy and Digital Health
In light of the current situation, we are pleased to offer Telehealth services for mental or neurological disorders. We offer an online physical and cognitive rehabilitation program as an alternative treatment option to meet the individual needs of our clients.